Cargando…
The COVID‐19 Medicine Remdesivir Is Therapeutically Activated by Carboxylesterase‐1, and Excessive Hydrolysis Increases Cytotoxicity
Autores principales: | Shen, Yue, Eades, William, Yan, Bingfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250894/ https://www.ncbi.nlm.nih.gov/pubmed/34510834 http://dx.doi.org/10.1002/hep4.1736 |
Ejemplares similares
-
Remdesivir and COVID-19
por: Wang, Lei-Yun, et al.
Publicado: (2020) -
Remdesivir and COVID-19
por: Glaus, Matthew J, et al.
Publicado: (2020) -
Remdesivir and COVID-19
por: Dennis, Alicia
Publicado: (2020) -
Remdesivir and COVID-19
por: Edwards, Jessie K, et al.
Publicado: (2020) -
Fluorine impairs carboxylesterase 1-mediated hydrolysis of T-2 toxin and increases its chondrocyte toxicity
por: Jia, Yumeng, et al.
Publicado: (2022)